Yes, it sounds interesting. But when I see that they were at CHF 12500 in 2007 and fell by 93% in April 2014...I don't know.
•
22
•
True, the history looks really heavy at first glance. But it's fair to say:
It's not the same company today as it was back then. Kuros is now more of a medtech/orthobiologics play with MagnetOs as its product focus, i.e. a completely different business model than in the Cytos days. The old share price performance tends to show how brutally biotech can fail, but it says only a limited amount about the current setup.
In my view, what is more interesting is the strong sales growth, the initial profitability and whether they can continue this over the next few years.
It's not the same company today as it was back then. Kuros is now more of a medtech/orthobiologics play with MagnetOs as its product focus, i.e. a completely different business model than in the Cytos days. The old share price performance tends to show how brutally biotech can fail, but it says only a limited amount about the current setup.
In my view, what is more interesting is the strong sales growth, the initial profitability and whether they can continue this over the next few years.
••
@BeachPlease well then calculate the % we will gain if the old ATH is reached again. It would be worse if we had entered the market at CHF 12,500.
•
11
•